Ohgi M

No ORCID on file · 1 paper in corpus · active 2026
2026
Frontiers in medicine ·doi:10.3389/fmed.2026.1704529

BackgroundRelugolix, an oral gonadotropin-releasing hormone (GnRH) antagonist, represents a potentially effective and less invasive therapeutic approach for retained products of conception (RPOC). However, its impact on subsequent pregnancy…